You are here: Home » International » News » Others
Business Standard

Possible link between AstraZeneca's Covid vaccine and clots: EU regulator

Oxford pauses trial among children; UK offers alternative to under-30s

Coronavirus | AstraZeneca | Coronavirus Vaccine


Coronavirus, vaccine, ASTRAZENECA, OXFORD, covid, drugs, clinical trials
The EMA's safety committee, which was assessing the vaccine, has requested for more studies and changes to the current ones to get more information.

Europe's drug regulator on Wednesday found a possible link between AstraZeneca's Covid-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all available evidence.
“One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin,” the European Medicines Agency (EMA) said.
Meanwhile. a government committee in the UK advising on vaccinations has said people under the age of 30 should be offered an alternative to the vaccine. Altogether, 79 such cases have been reported in the country.
“Adults who are aged 18 to 29 years old who do not have an underlying health condition... should be offered an alternative Covid-19 vaccine in preference to the vaccine, where such an alternative vaccine is available," Wei Shen Lim of the Joint Committee on Vaccination and Immunisation said.
The University of Oxford also said it had paused a small UK trial testing the Covid-19 vaccine it developed with in children and teenagers, as it waits for more data on rare blood clotting issues in adults who received the shot.
The university, which helped develop the embattled vaccine, said in a statement that there were “no safety concerns” in the trial, but acknowledged fears over a potential link to clots by saying that it was awaiting additional data from Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) before restarting the study.
It is also a blow to AstraZeneca, which was a frontrunner in the race for making an effective vaccine against Covid-19 ever since it began working with the University of Oxford.
The EMA's safety committee, which was assessing the vaccine, has requested for more studies and changes to the current ones to get more information.
The warning could threaten the European Union’s vaccination campaign, which was just beginning to kick into a higher gear after a sluggish start.
The latest assessment of the Astra vaccine, which was developed with the University of Oxford, comes amid increasing public wariness about the shot, with patients from Bucharest to Calais canceling scheduled appointments as they await more clarity.
Concerns are growing that the setback with the Astra shot could mean the UK misses its target to vaccinate all adults by the end of July, although the government insists it remains on track.

Moderna rolled out in UK
The UK began giving the Moderna Inc. vaccine on Wednesday, bolstering Britain’s Covid-19 immunisation program amid ongoing concerns over potential side effects relating to AstraZeneca’s shot.
The Moderna vaccine, which is first being offered in Wales, is the UK’s third approved shot alongside those from AstraZeneca and partners Pfizer Inc. and BioNTech SE. The UK has ordered 17 million doses of Moderna’s two-shot vaccine, enough for 8.5 million people.               Reuters



What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.


Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 08 2021. 02:07 IST